Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-to-Participate-in-the-Piper-Sandler-35th-Annual-Healthcare-Conference/default.aspx
Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Reports-Third-Quarter-2023-Results/default.aspx
Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2023-Investor-Update-Call/default.aspx
Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Releases-New-IBS-C-and-CIC-Data-at-the-American-College-of-Gastroenterology-2023-Annual-Scientific-Meeting/default.aspx
Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Presents-Positive-Final-Data-from-STARS-Nutrition-a-Phase-II-Study-of-Apraglutide-in-Short-Bowel-Syndrome-with-Intestinal-Failure-SBS-IF-and-Colon-in-Continuity-CIC-at-United-European-Gastroenterology-Week/default.aspx
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-to-Present-New-Data-at-NASPGHAN-Annual-Meeting-Reinforcing-Impact-of-Linaclotide-on-Functional-Constipation-in-Children-and-Adolescents-Ages-6-17-Years-Old/default.aspx
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Reports-Second-Quarter-2023-Results-Raises-Full-Year-2023-LINZESS-U.S.-Net-Sales-and-Ironwood-Revenue-Guidance/default.aspx
Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2023-Investor-Update-Call/default.aspx
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-and-VectivBio-Announce-the-Completion-of-the-Tender-Offer-for-VectivBio-Shares/default.aspx
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-and-VectivBio-Announce-Expiration-of-Hart-Scott-Rodino-Waiting-Period-for-Proposed-Acquisition-of-VectivBio/default.aspx
